Welcome to our dedicated page for Cuprina Holdings (Cayman) SEC filings (Ticker: CUPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cuprina Holdings (Cayman) Limited (CUPR) SEC filings page provides access to the company’s regulatory reports as a foreign private issuer listed on The Nasdaq Capital Market. Cuprina files current reports on Form 6-K under the Securities Exchange Act of 1934, which include press releases and other information furnished to investors.
Recent Form 6-K filings referenced by the company include reports furnishing press releases about its joint venture with Aiodine Laboratory to develop and market a novel iodine-based wound care and antiseptic solution, its exclusive licensing of a UNIDO/GEF-demonstrated medical waste recycling technology for Singapore and other Southeast Asian markets, and its update on research collaborations with Singapore-based institutes on bullfrog-derived collagen peptides. Other 6-Ks report on corporate developments such as the appointment of a new Medical and Scientific Director and the licensing of an FDA-cleared medical maggot product, as well as changes in the company’s independent registered public accounting firm.
Cuprina also uses Form 6-K to disclose matters such as the resignation of certain officers and to furnish press releases related to operational and research milestones. In addition, the company has directed investors to its 6-K filing for detailed financial results for specific periods. Through these filings, investors can review information on chronic wound therapies, infertility-related initiatives, medical waste recycling activities and cosmeceutical research that the company chooses to furnish to the U.S. Securities and Exchange Commission.
On this page, users can track new 6-K submissions for CUPR as they are made available from EDGAR, and use AI-powered summaries to quickly understand the key points, including financial disclosures, auditor changes, strategic agreements and other reportable events described by Cuprina.
Cuprina Holdings (Cayman) LTD filed a Form 3 identifying CHAN Tat Jing as an officer of the company, serving as Chief Financial Officer. The filing lists no stock or option transactions, and the transaction summary shows zero buys, sells, exercises, gifts, or other movements.
Cuprina Holdings (Cayman) LTD director and CEO QUEK David Yong Qi has filed an initial Form 3 showing indirect ownership in Class B Ordinary Shares. The filing reports 3,119,859 Class B Ordinary Shares held by Cuprina Holding Pte. Ltd. that are attributable to him through an ownership interest.
Cuprina Holding Pte. Ltd. holds a total of 14,085,000 Class B Ordinary Shares of the company, and Mr. Quek owns a 22.15% ownership interest in that entity. This Form 3 does not report new buying or selling activity; it establishes Mr. Quek’s existing indirect stake.
Cuprina Holdings (Cayman) LTD director KOH Pee Keat filed a Form 3 insider report for CUPR. The filing lists no buy, sell, acquire, or dispose transactions and shows no derivative positions in this dataset. It functions as a baseline insider ownership disclosure for this director.
Cuprina Holdings (Cayman) LTD director Teo Peng Kwang reported his existing indirect ownership of Class B Ordinary Shares. The filing shows 5,818,504 Class B Ordinary Shares held by Cuprina Holding Pte. Ltd. are attributed to him through his 41.31% interest in that entity, which in total holds 14,085,000 Class B Ordinary Shares. This Form 3 records holdings rather than any new share purchases or sales.
Cuprina Holdings (Cayman) LTD director files initial ownership report. Natasha Kaur Raina, a director of Cuprina Holdings (Cayman) LTD (ticker CUPR), submitted a Form 3, which is an initial statement of beneficial ownership of securities. The filing shows no reported transactions or derivative positions.
Cuprina Holdings (Cayman) LTD director and 10% owner LEE Jimmy Peng Siew filed an initial Form 3 reporting his indirect holdings in Class B Ordinary Shares. The filing shows 5,146,638 Class B Ordinary Shares held by Cuprina Holding Pte. Ltd. as the relevant block attributed to him.
Cuprina Holding Pte. Ltd. holds an aggregate of 14,085,000 Class B Ordinary Shares of the company, and Mr. LEE owns a 36.54% ownership interest in that entity. The filing records this position as indirect ownership, with no reported purchases, sales, or option exercises.
Cuprina Holdings (Cayman) Limited has called a May 14, 2026 annual general meeting to vote on wide‑ranging governance and capital structure changes. The board seeks approval for a share consolidation affecting both Class A and Class B Ordinary Shares to help regain compliance with Nasdaq’s $1.00 minimum bid rule.
Shareholders are asked to increase Class B voting power from 10 to 100 votes per share, double authorised capital after the consolidation, adopt new second amended and restated constitutional documents, and approve the Cuprina 2026 Employee Incentive Plan covering up to 15% of Class A shares. A key proposal would authorise future financings that may exceed 20% of outstanding Class A Ordinary Shares or result in a change of control under Nasdaq rules, potentially diluting existing holders.
Cuprina Holdings (Cayman) LTD director files initial ownership report with the SEC. NG Wei Chean is identified as a director of CUPR, but this Form 3 excerpt shows no reported transactions or specific share or derivative holdings for this insider.
Cuprina Holdings reports a key regulatory milestone and a governance upgrade. Its 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority for MEDIFLY, a medical-grade maggot debridement therapy. The SFDA has categorized MEDIFLY as a Medical Device–Drug combination product, primarily regulated under the medical device framework. This classification enables Cuprina to finalize scientific and technical requirements needed for commercial distribution across Saudi Arabia’s healthcare network, supporting its Middle East and North Africa expansion strategy.
The company also strengthened its Medical and Scientific Advisory Board by appointing Dr. Enming Yong, a consultant in endocrinology at Tan Tock Seng Hospital and Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine in Singapore. Under a strategic advisory agreement, Dr. Yong will guide scientific and development strategy, clinical oversight, strategic consultation, and trend analysis in endocrinology and chronic wound management, reinforcing Cuprina’s focus on patient safety and clinical excellence.
Cuprina Holdings (Cayman) Limited reported that it issued a press release on November 18, 2025 announcing the formation of a joint venture company with Aiodine Laboratory. The joint venture is intended to develop and market a novel iodine-based solution as a new wound care therapy. The press release describing this collaboration is included as Exhibit 99.1 to this Form 6-K.